Answers are grounded in this paper and cite their sources.
Scoping review explores iron and selenium use to enhance ferroptosis in breast cancer, suggesting future research avenues.
The tumor microenvironment of breast cancer presents high complexity and resistance to conventional therapies. Ferroptosis, a programed cell death that is dependent on iron and characterized by lipid peroxidation, arises as a promising therapeutic goal. This scoping review mapped evidence on the exogenous use of iron and selenium, in conventional or nano-particulated forms, in the modulation of ferroptosis as therapeutic strategy for breast cancer treatment, identifying knowledge gaps and opportunities for future research. We performed a scoping review and the methodology followed the guidelines of the Joanna Briggs Institute (JBI) and PRISMA-ScR. We made a systematic search in five data bases (Embase, Lilacs, PubMed (MEDLINE), Scopus, and Web of Science) between the years 2012 and 2025. Among 2.723 identified publications, we selected 48 studies. The results revealed predominance of nanoplatforms of iron (97.9%), focused on the Fenton reaction. The modulation of selenium for inactivation of GPX4 was shown to be effective, though still little-explored (n = 1). We evidenced that the induction of ferroptosis potentializes tumor immunogenicity and the effectiveness of combined therapies. We conclude that the field is under development; thus, the diversification of metabolic targets and trials of chronic toxicity are fundamental steps for future clinical research.
No takes yet. Share an insight, caveat, or question.
Libório et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: